XML 12 R2.htm IDEA: XBRL DOCUMENT v3.8.0.1
Condensed Consolidated Balance Sheets - USD ($)
Mar. 31, 2018
Dec. 31, 2017
Current assets:    
Cash and cash equivalents $ 37,508,863 $ 23,786,579
Short-term investments 75,259,889 103,638,844
Accounts receivable 5,147,851 6,003,205
Accounts receivable from affiliated entities 2,242,569 486,619
Prepaid expenses and other current assets 2,002,015 2,600,906
Prepaid expenses and other current assets from affiliated entities 1,674,981 1,846,007
Total current assets 123,836,168 138,362,160
Fixed assets, net 17,486,103 18,320,176
Investment in affiliated entity - GeneOne 10,467,711 9,069,401
Investment in affiliated entity - PLS 3,307,192 2,325,079
Intangible assets, net 5,605,667 6,009,729
Goodwill 10,513,371 10,513,371
Other assets 2,448,628 2,639,354
Total assets 173,664,840 187,239,270
Current liabilities:    
Accounts payable and accrued expenses 15,825,207 23,278,798
Accounts payable and accrued expenses due to affiliated entities 1,298,741 926,943
Accrued clinical trial expenses 8,428,881 8,611,892
Common stock warrants 488,636 360,795
Deferred revenue 24,088,288 1,175,353
Deferred revenue from affiliated entities 56,167 174,110
Deferred rent 928,098 877,535
Other liabilities 261,325 0
Total current liabilities 51,375,343 35,405,426
Deferred revenue, net of current portion 203,322 215,853
Deferred rent, net of current portion 8,966,846 9,104,416
Deferred tax liabilities 24,766 24,766
Total liabilities 60,570,277 44,750,461
Stockholders’ equity:    
Preferred stock 0 0
Common stock 90,705 90,358
Additional paid-in capital 668,844,504 665,775,504
Accumulated deficit (555,475,779) (523,356,317)
Accumulated other comprehensive loss (461,136) (117,005)
Total Inovio Pharmaceuticals, Inc. stockholders’ equity 112,998,294 142,392,540
Non-controlling interest 96,269 96,269
Total stockholders’ equity 113,094,563 142,488,809
Total liabilities and stockholders’ equity $ 173,664,840 $ 187,239,270